Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth K W To

Showing results (11-20 of 100) with videos related to

Pageof 10
Sort By:
Current Cancer Drug Targets|March 8, 2022
Mesenchymal Epithelial Transition (MET): A Key Player in Chemotherapy Resistance and an Emerging Target for Potentiating Cancer ImmunotherapyKenneth K W To, William C S Cho
Pharmacogenomics|August 2, 2014
Expression and activity of ABCG2, but not ABCB1 or OATP1B1, are associated with cholesterol levels: evidence from in vitro and in vivo experimentsKenneth K W To, Miao Hu, Brian Tomlinson
Expert Opinion on Drug Discovery|June 1, 2021
An overview of rational design of mRNA-based therapeutics and vaccinesKenneth K W To, William C S Cho
Cancer Drug Resistance (Alhambra, Calif.)|September 30, 2022
Exosome secretion from hypoxic cancer cells reshapes the tumor microenvironment and mediates drug resistanceKenneth K W To, William C S Cho
Current Molecular Pharmacology|February 14, 2022
Drug Repurposing for Cancer Therapy in the Era of Precision MedicineKenneth K W To, William C S Cho
ISRN Oncology|July 11, 2012
Adverse Cell Culture Conditions Mimicking the Tumor Microenvironment Upregulate ABCG2 to Mediate Multidrug Resistance and a More Malignant PhenotypeGrace M Y Cheng, Kenneth K W To
Molecular and Cellular Biology|September 7, 2006
Aberrant promoter methylation of the ABCG2 gene in renal carcinomaKenneth K W To, Z Zhan, Susan E Bates
Cancer Drug Resistance (Alhambra, Calif.)|October 15, 2024
Competing endogenous RNAs (ceRNAs) and drug resistance to cancer therapyKenneth K W To, Hang Zhang, William C Cho
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|February 3, 2025
Effect of Extracellular Vesicles Derived From Tumor Cells on Immune EvasionXuanfan Liu, Kenneth K W To, Qinsong Zeng, et al.
Molecular Cancer|March 1, 2023
CD39/CD73/A2AR pathway and cancer immunotherapyChenglai Xia, Shuanghong Yin, Kenneth K W To, et al.
Pageof 10

Showing results (11-20 of 100) with videos related to

Sort By:
Pageof 10
Current Cancer Drug Targets|March 8, 2022
Mesenchymal Epithelial Transition (MET): A Key Player in Chemotherapy Resistance and an Emerging Target for Potentiating Cancer ImmunotherapyKenneth K W To, William C S Cho
Pharmacogenomics|August 2, 2014
Expression and activity of ABCG2, but not ABCB1 or OATP1B1, are associated with cholesterol levels: evidence from in vitro and in vivo experimentsKenneth K W To, Miao Hu, Brian Tomlinson
Expert Opinion on Drug Discovery|June 1, 2021
An overview of rational design of mRNA-based therapeutics and vaccinesKenneth K W To, William C S Cho
Cancer Drug Resistance (Alhambra, Calif.)|September 30, 2022
Exosome secretion from hypoxic cancer cells reshapes the tumor microenvironment and mediates drug resistanceKenneth K W To, William C S Cho
Current Molecular Pharmacology|February 14, 2022
Drug Repurposing for Cancer Therapy in the Era of Precision MedicineKenneth K W To, William C S Cho
ISRN Oncology|July 11, 2012
Adverse Cell Culture Conditions Mimicking the Tumor Microenvironment Upregulate ABCG2 to Mediate Multidrug Resistance and a More Malignant PhenotypeGrace M Y Cheng, Kenneth K W To
Molecular and Cellular Biology|September 7, 2006
Aberrant promoter methylation of the ABCG2 gene in renal carcinomaKenneth K W To, Z Zhan, Susan E Bates
Cancer Drug Resistance (Alhambra, Calif.)|October 15, 2024
Competing endogenous RNAs (ceRNAs) and drug resistance to cancer therapyKenneth K W To, Hang Zhang, William C Cho
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|February 3, 2025
Effect of Extracellular Vesicles Derived From Tumor Cells on Immune EvasionXuanfan Liu, Kenneth K W To, Qinsong Zeng, et al.
Molecular Cancer|March 1, 2023
CD39/CD73/A2AR pathway and cancer immunotherapyChenglai Xia, Shuanghong Yin, Kenneth K W To, et al.
Pageof 10